ClinicalTrials.gg
CompletedNCT00808769Updated Jun 1, 2015Results posted

Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression

A Phase 4 interventional study of Zegerid® and Prilosec OTC® in Normal Healthy Subject Population, sponsored by Procter and Gamble. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-01.

Sponsored by Procter and Gamble · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to compare Prilosec OTC® and Zegerid® in their effects on gastric acid suppression.

02

Conditions studied

  • Normal Healthy Subject Population
03

In context

Lead sponsor

Procter and Gamble is the lead sponsor of 83 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal subjects who are 18-65 years of age;
  • Non- females or those using

Exclusion criteria

Exclusion Criteria:

  • History of significant GI disease
  • Any significant medical illness
  • History of , allergy or intolerance to omeprazole or other proton pump inhibitors;
  • Currently using GI medications
  • GI disorder or surgery leading to impaired drug absorption
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    1

    Zegerid®

    Drug: Zegerid®

  • Experimental
    2

    Prilosec OTC®

    Drug: Prilosec OTC®

Interventions

  • DrugZegerid®

    capsule(20 mg omeprazole/sodium bicarbonate), single dose

  • Omeprazole-magnesium 20.6 mg, tablet, single dose

06

What researchers measure

Primary outcomes

  1. The Mean Percent Time Gastric pH > 4.0 on Day 1

    In this study, there was evidence of gastric pH probe failure and a high incidence of biologically improbable pH measurements (sustained pH \< 1.0) that bring the validity of the results into question. The results of this study are, therefore, inconclusive.

    Time frame: continuously over a 24 hour period

07

Results

Posted Apr 27, 2011
Limitations and caveats
Results of this study were uninterpretable as noted in the Analysis Population Description.

Participant flow

The study period of this study was November 25 to December 21, 2008

First Intervention
Participant flow — First Intervention
MilestoneZegerid® Then Prilosec OTC®Prilosec OTC® Then Zegerid®
Started1515
Completed1515
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneZegerid® Then Prilosec OTC®Prilosec OTC® Then Zegerid®
Started1515
Completed1515
Not completed00

Outcome measures

PrimaryThe Mean Percent Time Gastric pH > 4.0 on Day 1

In this study, there was evidence of gastric pH probe failure and a high incidence of biologically improbable pH measurements (sustained pH \< 1.0) that bring the validity of the results into question. The results of this study are, therefore, inconclusive.

Time frame:
continuously over a 24 hour period

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zegerid® Then Prilosec OTC®—0/30 (0%)0/30 (0%)
Prilosec OTC® Then Zegerid®—0/30 (0%)0/30 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 years0
Between 18 and 65 years30
>=65 years0
Age, Continuous
Age, Continuous(years)All Study Participants
Mean26.4 ± 4.47
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female8
Male22
Region of Enrollment
Region of Enrollment(participants)All Study Participants
United States30
08

Study locations

1 site
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2008
First posted
Dec 16, 2008
Start
Nov 2008
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Apr 27, 2011
Last update
Jun 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00808769
Lead sponsor
Procter and Gamble
Responsible party
Sponsor
First posted
Dec 16, 2008
Start date
Nov 2008
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Apr 27, 2011
Last update
Jun 1, 2015

Study contacts

John McRorie, PhD, FACG, AGAF
study director · Procter and Gamble

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omeprazole

Start the discussion